Introduction

The EACR Conference on Liquid Biopsies will provide a comprehensive overview of liquid biopsies in cancer. It will cover what is already in clinical practice, what is on the horizon for liquid biopsies in cancer patient management and the latest new techniques for high sensitivity profiling of solid tumours in the blood.

View the onsite guide

This meeting will develop our understanding of the potential of liquid biopsies. This includes to support early detection of cancer; as prognostic, pharmacodynamic and predictive biomarkers of treatment efficacy and resistance; and for patient monitoring, including of minimal residual disease for early identification of disease relapse. It will also explore how liquid biopsies can be incorporated in cancer patient management and how implementation of liquid biopsies can change clinical practice.

Topics to be covered

• From basic discoveries to clinical application using minimally invasive clinical bio-specimens.

• Circulating Tumour DNA

• Predicting immunotherapy responses

• CTC’s

• ctDNA-MRD

• ctDNA, Methylation & Fragmentomics

Target audience

Translational scientists, biologists, geneticists, clinical chemists, molecular pathologists, oncologists, patient advocates, primary care (GPs), radiologists, clinical and non-clinical trainees, biotech and diagnostic companies, Pharma, bioengineers.

Scientific Programme Committee

• Alberto  Bardelli, University of Turin, Italy

• Carlos Caldas, CRUK Cambridge Institute, UK

• Caroline Dive CRUK Manchester Institute, UK (Chair)

• Evi Lianidou, University of Athens, Greece

• Nickolas Papadopoulos, Johns Hopkins Medicine, USA

Follow us on twitter for updates @EACRnews and engage with the conference with #eacrLiquidBiopsies

Above: the beautiful city of Bergamo